Jefferies Group's XBI Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 1.72 M shares of State Street SPDR S&P Biotech ETF (XBI) worth $209.12 M, representing 1.07% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in XBI, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 636,869 shares. Largest reduction occurred in Q4 2023, reducing 811,816 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's State Street SPDR S&P Biotech ETF (XBI) Holding Value Over Time
Track share changes against reported price movement
Quarterly State Street SPDR S&P Biotech ETF (XBI) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2022 | +745,217 | New Buy | 745,217 | $83.00 |
| Q1 2023 | +282,193 | Add 37.87% | 1.03 M | $76.21 |
| Q2 2023 | -25,036 | Reduce 2.44% | 1 M | $83.20 |
| Q3 2023 | +5,415 | Add 0.54% | 1.01 M | $73.02 |
| Q4 2023 | -811,816 | Reduce 80.55% | 195,973 | $89.29 |
| Q1 2024 | +612,688 | Add 312.64% | 808,661 | $94.89 |
| Q2 2024 | -760,730 | Reduce 94.07% | 47,931 | $92.71 |
| Q3 2024 | +21,512 | Add 44.88% | 69,443 | $98.80 |
| Q4 2024 | +541,290 | Add 779.47% | 610,733 | $90.06 |
| Q1 2025 | +184,277 | Add 30.17% | 795,010 | $81.10 |
| Q2 2025 | +636,869 | Add 80.11% | 1.43 M | $82.93 |
| Q3 2025 | +74,191 | Add 5.18% | 1.51 M | $100.20 |
| Q4 2025 | +209,019 | Add 13.88% | 1.72 M | $121.93 |
Jefferies Group's State Street SPDR S&P Biotech ETF Investment FAQs
Jefferies Group first purchased State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, acquiring 745,217 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held State Street SPDR S&P Biotech ETF (XBI) for 13 quarters since Q4 2022.
Jefferies Group's largest addition to State Street SPDR S&P Biotech ETF (XBI) was in Q4 2022, adding 745,217 shares worth $61.85 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 1,715,089 shares of State Street SPDR S&P Biotech ETF (XBI), valued at approximately $209.12 M.
As of the Q4 2025 filing, State Street SPDR S&P Biotech ETF (XBI) represents approximately 1.07% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in State Street SPDR S&P Biotech ETF (XBI) was 1,715,089 shares, as reported at the end of Q4 2025.